0001209191-18-055181.txt : 20181016
0001209191-18-055181.hdr.sgml : 20181016
20181016180515
ACCESSION NUMBER: 0001209191-18-055181
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181015
FILED AS OF DATE: 20181016
DATE AS OF CHANGE: 20181016
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: POTTER MYRTLE S
CENTRAL INDEX KEY: 0001214130
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37418
FILM NUMBER: 181125144
MAIL ADDRESS:
STREET 1: 10 FINDERNE AVE
CITY: BRIDGEWATER
STATE: NJ
ZIP: 08807
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Axovant Sciences Ltd.
CENTRAL INDEX KEY: 0001636050
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: D0
FISCAL YEAR END: 0331
BUSINESS ADDRESS:
STREET 1: 20-22 BEDFORD ROW
CITY: LONDON
STATE: X0
ZIP: WC1R 4JS
BUSINESS PHONE: 441-295-5950
MAIL ADDRESS:
STREET 1: 20-22 BEDFORD ROW
CITY: LONDON
STATE: X0
ZIP: WC1R 4JS
FORMER COMPANY:
FORMER CONFORMED NAME: Axovant Sciences, Inc.
DATE OF NAME CHANGE: 20150324
FORMER COMPANY:
FORMER CONFORMED NAME: Roivant Neurosciences Ltd.
DATE OF NAME CHANGE: 20150309
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2018-10-15
0
0001636050
Axovant Sciences Ltd.
AXON
0001214130
POTTER MYRTLE S
C/O AXOVANT SCIENCES INC.
11 TIMES SQUARE, 33RD FLOOR
NEW YORK
NY
10036
1
0
0
0
Stock Option ( Right to Buy)
2.37
2018-10-15
4
A
0
150000
0.00
A
2028-10-14
Common Shares
150000
150000
D
The common shares underlying this option vest over a period of three years, with one-third of the common shares vesting on each of the first, second and third anniversaries of September 26, 2018, the date of the Reporting Person's appointment to the Issuer's Board of Directors. The option allows for early exercise, subject to the Issuer's repurchase option with respect to any unvested common shares. All common shares underlying such option will become fully vested upon a change in control, as that term is defined in the Issuer's 2015 Equity Incentive Plan.
/s/ John T. McKenna, Attorney-in-Fact
2018-10-16